Novocure Reports Second Quarter 2025 Financial Results Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress 2025, selected as Best of ASCO 2025 and published in the Journal of Clinical Oncology BAAR, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. ...